BioXcel Therapeutics Inc. (NASDAQ: BTAI)
$1.29
+0.0650 ( +5.33% ) 874.9K
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Market Data
Open
$1.29
Previous close
$1.22
Volume
874.9K
Market cap
$48.04M
Day range
$1.17 - $1.47
52 week range
$1.04 - $12.21
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Jun 11, 2024 |
4 | Insider transactions | 1 | Jun 11, 2024 |
4 | Insider transactions | 1 | Jun 11, 2024 |
4 | Insider transactions | 1 | Jun 11, 2024 |
4 | Insider transactions | 1 | Jun 11, 2024 |
4 | Insider transactions | 1 | Jun 06, 2024 |
8-k | 8K-related | 14 | May 09, 2024 |
10-q | Quarterly Reports | 85 | May 09, 2024 |
def | Proxies and info statements | 8 | Apr 29, 2024 |
8-k | 8K-related | 50 | Apr 22, 2024 |